Lipid 360° Learning Center:
Advancing Evidence-Based Care in Lipid Management

Through expert interviews, interactive case discussions, multidisciplinary panels, and patient perspectives, leading global experts in cardiovascular medicine, lipidology, and endocrinology share the latest evidence alongside real-world clinical insights. Empower clinicians with practical strategies for optimizing lipid management across the spectrum of dyslipidemias from elevated LDL-C and lipoprotein(a) to severe hypertriglyceridemia and rare genetic disorders such as familial chylomicronemia syndrome (FCS).

Your Comprehensive Hub for Advancing
Evidence-Based Care in Lipid Management

Join our international community of cardiologists, lipidologists, primary care physicians, and endocrinologists by exploring curated educational resources and bringing this knowledge back to your teams to advance patient care and improve outcomes.

Obicetrapib (CETP Inhibitor)

Novel Pathway

An investigational, highly selective cholesteryl ester transfer protein (CETP) inhibitor being studied for the treatment of elevated levels of low-density lipoprotein cholesterol (LDL-C).

Lipid Disorders Global Statistics

Key prevalence and treatment gap metrics across LDL-C, Lp(a), and hypercholesterolemia.

24.1%

prevalence of hypercholesterolemia in adults (meta-analysis).

JHPN 2025

~50%

of high-risk patients fail to achieve LDL-C targets despite statin therapy.

AACE 2025

20–25%

of the population has elevated Lp(a), an independent causal ASCVD risk factor.

EHJ 2025

Curated Activities

Explore CME and clinical practice programs across FCS/SHTG, CETP/obicetrapib, LDL-C therapies, and women’s heart health.

FCS & Severe Hypertriglyceridemia

LOVE STORY: Lipid Education for Women's Heart Health

Leading Global Experts

Our distinguished multidisciplinary faculty represents the pinnacle of expertise in lipid management, bringing together renowned clinicians, researchers, and thought leaders from the world's most prestigious medical institutions.